| 1691 |
LUCIBELZU |
BELZUTIFAN 40 MG |
TABLET |
BOTTLE |
TREATMENT OF ADULT PATIENTS WITH VON HIPPEL-LINDAU DISEASE WHO REQUIRE THERAPY FOR ASSOCIATED RENALCELL CARCINOMA. |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
08 L 1187/24 |
22-AUG-2024 |
21-AUG-2027 |
View |
| 1692 |
LUCIBET |
BICTEGRAVIR SODIUM 50 MG, EMTRICITABINE 200 MG, TENOFOVIR ALAFENAMIDE 25 MG |
TABLET |
BOTTLE |
AS A COMPLETE REGIMEN FOR THE TREATMENTOF HIV-1 INFECTION IN ADULT AND PEDIATRIC PATIENTS WIEGHING AT LEAST 14 KG |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
01 L 1291/25 |
03-FEB-2025 |
02-FEB-2030 |
View |
| 1693 |
LUCIBINIM |
BINIMETINIB 15 MG |
TABLET |
BOTTLE |
IN COMBINATION WITH ENCORAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLET OR METASTATIC MELANOMA WITH A BRAF V600E OR V600E MUTATION |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
09 L 1194/24 |
24-SEP-2024 |
23-SEP-2029 |
View |
| 1694 |
LUCIBOSE |
BOSENTAN 125 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN ADULT TO IMPROVE EXCERCISE ABILITY AND TO DECREASE CLINICAL WORSENING, IN PEDIATRIC PTIENTS AGED 3 YEARS AND OLDER WITH IDIOPATHIC OR CONGENITAL PAH TO IMPROVE PULMONARY VASCULAR RESISTANC WHICH IS EXPECTED TO RESULT IN AN IMPROVEMENT IN EXCERCISE ABILITY |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
03 L 1319/25 |
07-APR-2025 |
06-APR-2030 |
View |
| 1695 |
LUCIBOSE |
COBIMETINIB 20 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, INCOMBINATION WITH VEMURAFENIB, AS A SINGLE AGENT FOR THE TREATMENT OF ADULT PATIENTS WITH HISTIOCYTIC NEOPLASMS |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
03 L 1317/25 |
07-APR-2025 |
06-APR-2030 |
View |
| 1696 |
LUCIBRIGA 180 |
BRIGATINIB 180 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE-POSITIVE METASTATIC NON SMALL CELL LUNG CANCER |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
02 L 1066/24 |
14-MAR-2023 |
13-MAR-2027 |
View |
| 1697 |
LUCIBRIGA 90 |
BRIGATINIB 90 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE-POSITIVE METASTATIC NON SMALL CELL LUNG CANCER |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
02 L 1065/24 |
14-MAR-2023 |
13-MAR-2027 |
View |
| 1698 |
LUCIBRU |
IBRUTINIB 140 MG |
TABLET |
BOTTLE |
ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY, CHRONIC LYPHOCYTIC LEUKEMIA |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
07 L 1141/24 |
12-JUL-2024 |
11-JUL-2027 |
View |
| 1699 |
LUCICABER |
CABERGOLINE 0.5 MG |
TABLET |
BOTTLE |
FOR THE PREVENTION OF THE ONSET OF PHYSIOLOGICAL LACTATION IN THE PUERPERIUM FOR CLEARLY DEFINED MEDICAL REASON, FOR THE TREATMENT OF PATHOLOGICAL HYPERPROLACTINAEMIA |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
03 L 1322/25 |
28-MAR-2025 |
27-MAR-2030 |
View |
| 1700 |
LUCICABOZ |
CABOZANTINIB 20 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF PATIENTS WITH PROGRESSIVE, METASTATIC MEDULLARY THYROID CANCER. |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
04 L 0958/23 |
19-APR-2023 |
18-APR-2026 |
View |
